Lp(a) With CCTA Assessed Parameters and Clinical Outcomes

Study Overview
=================
Brief Summary
-----------------
Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular events, although the underlying mechanism remains unclear. This study evaluated the relationship between Lp(a) and high-risk attributes (HRA) by coronary computed tomography angiography (CCTA) as well as their prognostic value.

Official Title
-----------------
Association of Lipoprotein (a) With Coronary CTA Assessed High Risk Coronary Disease Attributes and Cardiovascular Outcomes

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Coronary CTA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Lp(a) meaured within 1 week of CCTA examination. Exclusion Criteria: unstable angina pectoris acute myocardial infarction New York Heart Association class III-IV heart failure with a history of bypass surgery active infection respiratory failure chronic kidney disease (estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m2) liver dysfunction (liver enzyme >3 upper reference limit [URL] or bilirubin >2 URL) malignancy systemic connective tissue disease poor CCTA imaging quality not suitable for analysis other situations not suitable for the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Patients with Lp(a) <60mg/dL | Diagnostic Test: Coronary CTA<br>* Patients receive coroanry CTA at the discretion of the physicians in charge. And parameters including plaque burden, minimal lumen area, diameter stenosis, total plaque volume, high-risk plaque characteristics, fractional flow reserve, pullback pressure gradient, fat attenuation index will be analyzed.<br>|
| Group 2<br>Patients with Lp(a) ≥60 mg/dL | Diagnostic Test: Coronary CTA<br>* Patients receive coroanry CTA at the discretion of the physicians in charge. And parameters including plaque burden, minimal lumen area, diameter stenosis, total plaque volume, high-risk plaque characteristics, fractional flow reserve, pullback pressure gradient, fat attenuation index will be analyzed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association of Lp(a) level with CCTA measured Parameters | Association of Lp(a) level with CCTA measured total plaque volume | at the index procedure | 
| Association of Lp(a) level with CCTA measured Parameters | Association of Lp(a) level with CCTA measured fractional flow reserve | at the index procedure | 
| Association of Lp(a) level with CCTA measured Parameters | Association of Lp(a) level with CCTA measured pullback pressure gradient | at the index procedure | 
| Association of Lp(a) level with CCTA measured Parameters | Association of Lp(a) level with CCTA measured fat attenuation index | at the index procedure | 
| Association of Lp(a) level with CCTA measured Parameters | Association of Lp(a) level with CCTA measured high-risk plaque characteristics | at the index procedure | 
| Major adverse cardiac events | a composite of cardiac death, any myocardial infarction, and stroke | at 24 months from index procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac death | Cardiac death | at 24 months from index procedure | 
| Myocardial infarction | Myocardial infarction | at 24 months from index procedure | 
| Stroke | stroke | at 24 months from index procedure |